Rayan Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 05-07-2024
- Paid Up Capital ₹ 4.66 M
as on 05-07-2024
- Company Age 37 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.65 M
as on 05-07-2024
- Revenue %
(FY 2022)
- Profit -120.00%
(FY 2022)
- Ebitda -120.00%
(FY 2022)
- Net Worth -0.96%
(FY 2022)
- Total Assets %
(FY 2022)
About Rayan Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.66 M.
The company currently has active open charges totaling ₹7.65 M.
Subhadra Pedamallu, Ranganayakamurthy Pedamallu, and Venkata Grandi serve as directors at the Company.
- CIN/LLPIN
U24200AP1987PLC007320
- Company No.
007320
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
30 Mar 1987
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Andhra Pradesh, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rayan Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ranganayakamurthy Pedamallu  | Managing Director | 10-Feb-2006 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Subhadra Pedamallu | Director | 10-Feb-2006 | Current |
| Venkata Grandi | Director | 13-Mar-2006 | Current |
Financial Performance of Rayan Pharma.
Rayan Pharma Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 120% decrease in profit. The company's net worth dipped by a decrease of 0.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rayan Pharma?
In 2022, Rayan Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Andhra Pradesh State Financial Corporation Creation Date: 24 Mar 1999 | ₹2.00 M | Open |
Andhra Pradesh State Financial Corporation Creation Date: 06 Jun 1997 | ₹3.20 M | Open |
Andhra Pradesh State Financial Corporation Creation Date: 14 Nov 1992 | ₹0.73 M | Open |
How Many Employees Work at Rayan Pharma?
Unlock and access historical data on people associated with Rayan Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rayan Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rayan Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
